Dominated by current smoker males with a median age of 58 years, often diagnosed with NSCLC at late stage IVA, the majority received chemotherapy, and only five were treated with erlotinib and were not selected according to EGFR status. Here, EGFR is linked to non-small cell lung carcinoma.